Unrealized gains (losses) on investments Unrealized Gain (Loss) on Investments Earn-Out Shares (non-vested) Earn Out Shares Nonvested [Member] Earnout or earn-out refers to a pricing structure in mergers and acquisitions where the sellers must "earn" part of the purchase price based on the performance of the business. Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] RSL 2021 EIP Roivant Sciences Ltd2021 Equity Incentive Plan [Member] The Roivant Sciences Ltd Equity Incentive Plan 2021 also known as (the "RSL 2021 EIP"). Underwritten Public Offering Underwritten Offering [Member] Underwritten Offering Statistical Measurement [Domain] Statistical Measurement [Domain] 2025 Stock Repurchase Program 2025 Stock Repurchase Program [Member] 2025 Stock Repurchase Program Investments Investment, Policy [Policy Text Block] Tranche Type [Axis] Tranche Type [Axis] Tranche Type Restricted cash (included in “Other current assets”) Restricted Cash, Current Award Timing Predetermined Award Timing Predetermined [Flag] Related Party Transaction [Axis] Related Party Transaction [Axis] Common shares aggregate offering price authorized Common Shares Offering Price Authorized The common shares aggregate offering price authorized to issue under equity offering program. Asset Class [Axis] Asset Class [Axis] Entity File Number Entity File Number Additional Paid-in Capital Additional Paid-in Capital [Member] Tabular List, Table Tabular List [Table Text Block] Basic and diluted net (loss) income per common share: Earnings Per Share, Basic [Abstract] Significant Accounting Policies /Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Other comprehensive income: Other Comprehensive Income (Loss), Tax [Abstract] U.S. Treasury securities, available-for-sale, Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Basic net (loss) income per common share (in dollars per share) Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Earn-Out Shares [Table] Earn-Out Shares [Table] Schedule for earn-out shares. Loss from discontinued operations before income taxes attributable to noncontrolling interests Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Accounts payable Increase (Decrease) in Accounts Payable, Trade Entity Addresses [Table] Entity Addresses [Table] Award Date [Axis] Award Date [Axis] Wholly-owned Subsidiaries Address - Switzerland Wholly-owned Subsidiaries Address - Switzerland [Member] Wholly-owned Subsidiaries Address - Switzerland Stock, Class of Stock [Table] Stock, Class of Stock [Table] Discount rate Measurement Input, Discount Rate [Member] Total other comprehensive income Other Comprehensive Income (Loss), Net of Tax Schedule of Significant Segment Expenses Schedule of Segment Reporting Information, by Segment [Table Text Block] Diluted income from discontinued operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Cost of revenues Operating Costs The total amount of operating cost and expense. Issuance of the Company’s common shares under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Schedule of Cash, Cash Equivalents, and Restricted Cash Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of Cash, Cash Equivalents, and Marketable Securities Cash, Cash Equivalent, and Investment [Table Text Block] U.S. Treasury securities, held-to-maturity, Gross Unrealized Gains Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain Measurement Input Type [Domain] Measurement Input Type [Domain] Dermavant assets Disposal Group, Including Discontinued Operation, Assets RSL RSL [Member] RSL Adjustment to Compensation, Amount Adjustment to Compensation Amount Principles of Consolidation Consolidation, Policy [Policy Text Block] Share-based compensation Share-Based Payment Arrangement, Noncash Expense Employee Stock Option Share-Based Payment Arrangement, Option [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Pre-tax impairment charges Asset Impairment Charges Shareholders’ equity attributable to Roivant Sciences Ltd. Equity, Attributable to Parent Research and development Disposal Group Including Discontinued Operation, Research And Development Expense Amount of research And development expense attributable to disposal group, including, but not limited to, discontinued operation. Insider Trading Policies and Procedures [Line Items] Share-based compensation expense Share-Based Payment Arrangement, Expense Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common shares issued (in Shares) Stock Issued During Period, Shares, New Issues Datavant Datavant [Member] Datavant Current assets: Assets, Current [Abstract] Total liabilities and shareholders’ equity Liabilities and Equity Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Net (Loss) Income per Common Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Liability instruments measured at fair value Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Concentrations Concentration Risk, Credit Risk, Policy [Policy Text Block] Available-for-Sale Securities Available-for-Sale Securities [Member] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Cover [Abstract] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Amounts reclassified from accumulated other comprehensive income Amounts reclassified from accumulated other comprehensive (loss) income Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Discontinued Operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] General and administrative share-based compensation General and Administrative Expense [Member] Equity Method Investment [Table] Equity Method Investment [Table] Purchase obligation, to be paid, year three Purchase Obligation, to be Paid, Year Three Net loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Accounting Policies [Abstract] Accounting Policies [Abstract] Restricted Stock Restricted Stock [Member] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Loss from continuing operations, net of tax Income (loss) from continuing operations, net of tax Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss from continuing operations before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Shell Company Entity Shell Company Other liabilities Other Liabilities, Noncurrent Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Underwritten Offering - Shares Purchased by RSL Underwritten Offering - Shares Purchased By RSL [Member] Underwritten Offering - Shares Purchased By RSL Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Activity for Performance Restricted Stock Units Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block] Gain on sale of Telavant net assets Gain on sale of Telavant net assets Gain on sale of telavant net assets Gain on sale of Telavant net assets Gain (Loss) On Sale Of Assets Amount of gain (loss) on sale of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. Frank Torti [Member] Frank Torti Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount Cash Cash Comprehensive loss attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Comprehensive (loss) income attributable to Roivant Sciences Ltd. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Measurement Input Type [Axis] Measurement Input Type [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Name Measure Name Loss from continuing operations, net of tax Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Operating lease liabilities Operating Lease, Liability, Current Schedule of Changes in Fair Value of the Level 3 Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Shareholders' Equity [Line Items] Class of Stock [Line Items] Milestone receivable from sale of discontinued operations Milestone Receivable From Sale Of Discontinued Operations Milestone Receivable From Sale Of Discontinued Operations Document Fiscal Period Focus Document Fiscal Period Focus Income from discontinued operations, net of tax Income from discontinued operations before income taxes attributable to Roivant Sciences Ltd. Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Taxes paid related to net settlement of equity awards Payments Of Taxes For The Repurchase Of Equity Payments of Taxes for the Repurchase of Equity. Total grant date fair values Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Granted Award Timing Method Award Timing Method [Text Block] Basic loss from continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Fair value of vested earnout liability Fair Value Of Vested Earnout Liability Fair Value Of Vested Earnout Liability Award Type [Axis] Award Type [Axis] Total assets Assets Investment, Name [Domain] Investment, Name [Domain] Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Cowen Cowen And Company LLC [Member] An affiliate with whom the entity entered into a sales agreement. Entity Trading Symbol Trading Symbol Other Noncash Other Amount of expense or loss included in net income that result in no cash flow, classified as other. Cash, Cash Equivalents, and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Entity Address, City or Town Entity Address, City or Town Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Cash, Cash Equivalents, and Marketable Securities [Line Items] Marketable Securities [Line Items] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Restricted common stock (non-vested) Restricted Stock Units (RSUs) [Member] President and Vant Chair President And Vant Chair [Member] Person with designation of RSI president and Vant chair. Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Number of vesting tranches Number of Vesting Tranches Number of Vesting Tranches Entity Emerging Growth Company Entity Emerging Growth Company U.S. Treasury securities, held-to-maturity, Fair Value Debt Securities, Held-to-Maturity, Fair Value Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Cash, Cash Equivalents, and Short-Term Investments [Abstract] Cash, Cash Equivalents, and Short-Term Investments [Abstract] Options outstanding, beginning balance (in shares) Options outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number PSUs performance condition satisfied (in shares) PSUs Performance Condition Satisfied, Shares PSUs Performance Condition Satisfied, Shares Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Number of shares acquired (in shares) Common Stock, Shares, Outstanding Compensation-related expenses Compensation Related Expense Compensation related to one time cash retention bonus award to employees. Schedule of Unrealized Positions for Marketable Securities Marketable Securities [Table Text Block] Chief Executive Officer Chief Executive Officer [Member] Plan Name [Axis] Plan Name [Axis] U.S. Treasury securities, held-to-maturity, Gross Unrealized Losses Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss PEO PEO [Member] Interest income Investment Income, Interest Number of shares issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Change in fair value of debt due to change in subsidiary credit risk Change In Fair Value Of Debt Due To Change In Subsidiary Credit Risk Change in fair value of debt due to change in subsidiary credit risk. Changes in assets and liabilities, net of effects from acquisition and divestiture: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Tranche Type [Domain] Tranche Type [Domain] Tranche Type [Domain] Earn-Out Shares [Line Items] Earn Out Shares [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Retained Earnings / (Accumulated Deficit) Retained Earnings [Member] Repayment of debt by subsidiary Repayment Of Long Term Debt And Convertible Debt By Subsidiary The cash outflow for debt repayment of long-term debt and convertible debt by subsidiary during the period. Number of RSUs and PSUs Number of CVARs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Income Statement [Abstract] Income Statement [Abstract] Income tax expense (benefit) Income Tax Expense (Benefit) Purchases of marketable securities Payments to Acquire Marketable Securities Basic income from discontinued operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Sale of Stock [Domain] Sale of Stock [Domain] Income tax payable Taxes Payable, Current Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Investments measured at fair value Aggregate fair value investment Investment Investments, Fair Value Disclosure Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Product and Service [Domain] Product and Service [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Issuance of the Company’s common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments (in shares) Stock Issued During Period, Shares, In Connection With Equity Incentive Plans And Tax Withholding Payments The number of shares issued in connection with equity incentive plans and tax withholding payments. Cash, cash equivalents, and marketable securities Total cash, cash equivalents, and marketable securities Cash, Cash Equivalents, and Short-Term Investments Diluted loss from continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Net (loss) income Net (loss) income Net income (loss) Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Reportable Segment Reportable Segment [Member] Reportable Segment Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Liabilities at fair value Liabilities, Fair Value Disclosure Selling, general and administrative Disposal Group Including Discontinued Operation, Selling General And Administrative Expense Amount of selling, general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation. Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Other current assets Increase (Decrease) in Other Current Assets Non-cash lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Consideration to be received from milestone Future Milestone To Be Received From Sale Of Assets The future milestone to be received from sale of assets. Gain (loss) on sale of business, accumulated other comprehensive income (loss) Disposal Group, Including Discontinued Operation, Accumulated Other Comprehensive Income (Loss) Disposal Group, Including Discontinued Operation, Accumulated Other Comprehensive Income (Loss) Proceeds from exercise of the Company’s and subsidiary stock options Proceeds from Stock Options Exercised City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Accrued expenses Total accrued expenses Accrued Liabilities, Current Contingencies Commitments and Contingencies, Policy [Policy Text Block] Non-vested balance, beginning (in shares) Non-vested balance, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Cash payment received for sale of assets Cash Payment Received For Sale Of Assets Amount of cash payment received for sale of assets. Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] General and administrative (includes $86,874 and $69,386 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $228,778 and $165,670 for the nine months ended December 31, 2025 and 2024, respectively) General and administrative expenses General and Administrative Expense Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Gain on sale of subsidiary interests Gain on sale of subsidiary interests Gain (Loss) on Sale of Interest in Subsidiary Gain (Loss) on Sale of Interest in Subsidiary November 2021 CVARs (non-vested) November 2021 Capped Value Appreciation Rights Grants [Member] Grant date of Capped Value Appreciation Rights (CVARs). Gross Unrealized Losses Debt Securities, Available-for-Sale and Held-to-Maturity, Cumulative Unrecognized Loss Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Subsequent Event Subsequent Event [Member] Description of Business and Liquidity [Line Items] Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] PEO Total Compensation Amount PEO Total Compensation Amount Change in fair value of investments Change in fair value of investments Gain (Loss) on Investments Money market funds Money Market Funds [Member] Amortized Cost Debt Securities, Available-for-Sale and Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss PSUs holding period before common shares may be sold by executive PSUs Holding Period Before Common Shares May be Sold by Executive PSUs Holding Period Before Common Shares May be Sold by Executive Pfizer Pfizer [Member] Name of the entity. Equity Components [Axis] Equity Components [Axis] Term of trailing trading days, weighted average price use to calculate performance condition of PSUs Period of Trailing Trading Days, Weighted Average Trading Price used to Calculate Performance Condition Period of Trailing Trading Days, Weighted Average Trading Price used to Calculate Performance Condition Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Product revenue, net Product [Member] Recent Transactions and Developments Recent Transactions And Developments Text Block [Text Block] The entire disclosure for recent transactions and development. Number of reportable segments Number of Reportable Segments MAAC Sponsor Patient Square Capital Limited Liability Company [Member] Name of the sponsor company. U.S. Treasury securities, available-for-sale, Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Ownership of subsidiary Ownership Of Subsidiary Percentage The percentage ownership of a subsidiary. Entity Address, Country Entity Address, Country Other Performance Measure, Amount Other Performance Measure, Amount Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Entity Address, State or Province Entity Address, State or Province Payments on principal portion of finance lease obligations Finance Lease, Principal Payments U.S. Treasury securities, available-for-sale Marketable Securities U.S. Government Treasury Securities Available-For-Sale, Current Amount of investment in marketable security, US Government Treasury Securities, available-for-saleclassified as current. Marketable Securities Marketable Securities, Policy [Policy Text Block] Impairment loss on operating lease right-of-use assets Operating Lease, Impairment Loss Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Gross Unrealized Gains Debt Securities, Available-for-Sale and Held-to-Maturity, Cumulative Unrecognized Gain Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Related and Nonrelated Parties [Domain] Related and Nonrelated Parties [Domain] Total current liabilities Liabilities, Current Individual: Individual [Axis] Proceeds from sale of subsidiary interests Proceeds from Divestiture of Interest in Consolidated Subsidiaries Other current assets Other Assets, Current Research and development share-based compensation Research and Development Expense [Member] Net cash used in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Purchase obligation, to be paid, year one Purchase Obligation, to be Paid, Year One Document Fiscal Year Focus Document Fiscal Year Focus Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Entity Interactive Data Current Entity Interactive Data Current Plan Name [Domain] Plan Name [Domain] President and Chief Investment Officer President And Chief Investment Officer [Member] Person with designation of president and chief investment officer. Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Equity [Abstract] Equity [Abstract] Change in fair value of liability instruments Gain (loss) on fair value of liability instruments Change in fair value of liability instruments Gain (Loss) On Fair Value Of Liability Instruments Amount of gain (loss) on fair value of liability instruments. Earn-Out Shares Earnout Shares [Member] The fair value of earn-out shares issued. Subsidiary Equity Incentive Plans Subsidiary Equity Incentive Plans [Member] Subsidiary equity incentive plans is a plan adopted by wholly owned and majority-owned or controlled subsidiaries of Roivant Sciences Ltd. Purchase obligation Purchase Obligation Segment Information Segment Reporting Disclosure [Text Block] Cash awards Cash Retention Awards The amount of cash retention awards granted to executives. Fair Value Measurements [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] US Treasury Securities US Treasury Securities [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Ownership [Domain] Ownership [Domain] Roche Transaction Roche Transaction [Member] Name of business transaction. Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Restricted stock units and performance stock units (non-vested) Restricted Stock And Performance Stock Units [Member] Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met and Share-based payment arrangement awarded for meeting performance target. Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Cost of revenues Disposal Group, Including Discontinued Operation, Costs of Goods Sold Schedule of One-time Cash Retention Awards Schedule Of Cash Retention Awards [Table Text Block] Tabular disclosure of cash retention awards. Volatility Measurement Input, Price Volatility [Member] Stock purchases Stock Repurchased During Period, Value Depreciation and amortization Depreciation, Depletion and Amortization Other assets Other Assets, Noncurrent Entity Central Index Key Entity Central Index Key Anti-FcRn franchise—other clinical and nonclinical Anti Fc Rn Franchise Other Clinical And Nonclinical [Member] Service provided for maintenance, diagnosis and treatment of physical and mental health, classified as other clinical and nonclinical PEO Name PEO Name Aggregate net proceeds from stock offering Sale of Stock, Consideration Received on Transaction Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Purchase obligation, to be paid, year two Purchase Obligation, to be Paid, Year Two Trading day period for earn-out shares Number Of Trading Days Allowed To Calculate Earn Out Share Price Threshold Number of trading days allowed to calculate earnout share price during vesting period, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Recent Transactions and Developments [Abstract] Recent Transactions and Developments [Abstract] Recent Transactions and Developments [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Balance at beginning of period Balance at end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Arrangement Duration Trading Arrangement Duration Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Earn-Out Shares [Abstract] Earn-Out Shares [Abstract] Earn-Out Shares [Abstract] Segments [Axis] Segments [Axis] Exercise Price Award Exercise Price Schedule of Activity for Capped Value Appreciation Rights Schedule Of Capped Value Appreciation Rights Stock Units Activity [Table Text Block] Tabular disclosure of the capped value appreciation rights stock units activity. Entity Filer Category Entity Filer Category Other research and development expenses Other Research And Development Expenses [Member] Represents other research and development related expenses. Class of Stock [Domain] Class of Stock [Domain] Amounts attributable to Roivant Sciences Ltd.: Income Amounts Attributable to Parent, Disclosures [Abstract] Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Closing price of common stock (in dollars per share) Share Price Other Payment for (Proceeds from) Other Investing Activity Subsequent Event Type [Axis] Subsequent Event Type [Axis] Share-Based Compensation and Other Compensation Plans Share-Based Payment Arrangement [Text Block] Repurchase of the Company's common shares (in shares) Stock Repurchased and Retired During Period, Shares Assets Assets [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Fair Value Measurements Fair Value Disclosures [Text Block] Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Shareholders’ equity: Equity, Attributable to Parent [Abstract] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Cash Bonus Program Cash Bonus Program [Member] The company approved a special one-time cash retention bonus award to its employees. Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Fair Value Debt Securities, Available-for-Sale and Held-to-Maturity, Fair Value Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively) Research and development expenses Research and Development Expense Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Investment, Name [Axis] Investment, Name [Axis] Loss from operations Disposal Group, Including Discontinued Operation, Operating Income (Loss) Operating lease liabilities, noncurrent Operating Lease, Liability, Noncurrent Balance Sheet Related Disclosures [Abstract] Ownership [Axis] Ownership [Axis] Change in fair value of debt Change In Fair Value Of Debt, Discontinued Operations Amount of noncash change in the fair value of debt related to discontinued operations Recent Transactions and Developments [Line Items] Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Fair Value as of Grant Date Award Grant Date Fair Value Entity Registrant Name Entity Registrant Name Change in fair value of debt Disposal Group Including Discontinued Operation, Change In Fair Value Of Debt Amount of change in fair value of debt attributable to disposal group, including, but not limited to, discontinued operation. Lease, discount rate Lessee, Operating Lease, Discount Rate Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Dermavant liabilities Disposal Group, Including Discontinued Operation, Liabilities Proceeds from sales of marketable securities Proceeds From Sale Of Marketable Securities Proceeds From Sale Of Marketable Securities General and administrative personnel-related expenses Personnel Related Expenses General And Administrative [Member] Represents General and Administrative Personnel Related Expenses. Other stock based awards and instruments issued Other Stock Based Awards And Instruments Issued [Member] The other stock based awards and instruments issued related to the awards consisting of stock units. Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Title and Position [Domain] Title and Position [Domain] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Proceeds from issuance of subsidiary common shares, net of issuance costs paid Proceed From Issuance Of Subsidiary Common Stock, Net Of Issuance Costs Proceed From Issuance Of Subsidiary Common Stock, Net Of Issuance Costs Document Quarterly Report Document Quarterly Report Total assets at fair value Assets, Fair Value Disclosure Schedule of Fair Value Calculation Using Significant Unobservable Inputs Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Share-based compensation Share Based Compensation, Discontinued Operations Amount of noncash expense for share-based payment arrangement attributable to discontinued operations. Number of operating segments Number of Operating Segments Accretion of discount and amortization of premium on marketable securities, net Accretion (Amortization) of Discounts and Premiums, Investments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Brepocitinib Brepocitinib [Member] Brepocitinib it represent selective inhibitor of non-receptor tyrosine-protein kinase TYK2 (tyrosine kinase 2) and tyrosine-protein kinase JAK1 (Janus kinase 1; JAK1) with potential immunomodulatory and anti-inflammatory activities. Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Axis] Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Non-PEO NEO Non-PEO NEO [Member] Issuance of the Company’s common shares under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Sale of Stock [Axis] Sale of Stock [Axis] Entity Addresses [Line Items] Entity Addresses [Line Items] U.S. Treasury securities, available-for-sale, Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Name Trading Arrangement, Individual Name Investment in equity securities, measurement input Fair Value Asset, Measurement Input Fair value asset, measurement input. Award Type [Domain] Award Type [Domain] Tranche Three Tranche Three [Member] Tranche Three Noncontrolling interests Equity, Attributable to Noncontrolling Interest Equity Awards Adjustments Equity Awards Adjustments [Member] Deconsolidation, gain (loss), amount Deconsolidation, Gain (Loss), Amount Other Other Noncash Income (Expense) Depreciation and amortization Depreciation and Amortization, Discontinued Operations Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Vesting of Earn-Out Shares Stock Issued During Period, Value, Vesting Of Earn-Out Shares Stock Issued During Period, Value, Vesting Of Earn-Out Shares Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Compensation Amount Outstanding Recovery Compensation Amount Sale of interests in subsidiary Noncontrolling Interest, Sale of Interests in Subsidiary Noncontrolling Interest, Sale of Interests in Subsidiary Purchase obligation, to be paid, remainder of fiscal year Purchase Obligation, to be Paid, Remainder of Fiscal Year Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Issuance of subsidiary common shares to the Company and cash contributions to majority-owned subsidiaries Issuance Of Subsidiary Common Shares To The Company And Capital Contributions To Subsidiaries Issuance Of Subsidiary Common Shares To The Company And Capital Contributions To Subsidiaries March 2020 CVARs March 2020 Capped Value Appreciation Rights Grants [Member] Grant date of Capped Value Appreciation Rights (CVARs). Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Anti-FcRn franchise—rheumatology diseases Anti Fc Rn Franchise Rheumatology Diseases [Member] Rheumatology diseases is a chronic progressive autoimmune disease that causes inflammation in the joints and surrounding tissues. Share Repurchase Program [Axis] Share Repurchase Program [Axis] Income tax (benefit) expense Discontinued Operation, Tax Effect of Discontinued Operation MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Name Awards Close in Time to MNPI Disclosures, Individual Name Earn-out share, measurement input Fair Value Earnout Shares Measurement Input The fair value measurement input for Earn-out shares. Restricted cash (included in “Other assets”) Restricted Cash, Noncurrent Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Country Region Country Region Financial Instruments [Domain] Financial Instruments [Domain] Cash decrease upon deconsolidation of subsidiaries Cash Divested from Deconsolidation Segments [Domain] Segments [Domain] Award Date [Domain] Award Date [Domain] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Reclassification of earn-out shares liability to additional paid-in capital upon vesting Reclassification Of Earn-Out Shares Liability To Additional Paid-In Capital Upon Vesting Reclassification Of Earn-Out Shares Liability To Additional Paid-In Capital Upon Vesting Performance restricted stock units Performance Shares [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Change in fair value of debt due to change in subsidiary credit risk Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) Operating lease right-of-use assets obtained and exchanged for operating lease liabilities Operating Lease Right-of-use Assets Obtained and Exchanged for Operating Lease Liabilities Operating Lease Right-of-use Assets Obtained and Exchanged for Operating Lease Liabilities Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Anti-FcRn franchise—dermatology diseases Anti Fc Rn Franchise Dermatology Diseases [Member] Dermatology diseases is a rare, chronic skin disease characterized by skin-specific disease activity, inflammation and eventually damage. Minimum Minimum [Member] Investment in Arbutus common shares Arbutus Biopharma Corporation [Member] The name of related party. Number of equity incentive plans (in plan) Number Of Equity Incentive Plans The number of equity incentive plans for the company during the period. Company Selected Measure Name Company Selected Measure Name Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts Payable, Current Proceeds from issuance of the Company’s common shares under employee stock purchase plan Proceeds from Stock Plans Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] All Executive Categories All Executive Categories [Member] Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 709,689,411 and 695,938,323 shares issued and outstanding at December 31, 2025 and March 31, 2025, respectively Common Stock, Value, Issued Description of Business and Liquidity [Abstract] Description of Business and Liquidity [Abstract] Description of Business and Liquidity [Abstract] Exercise and vesting of subsidiary share awards Exercise And Vesting Of Subsidiary Share Based Awards The amount recognized in equity in the period due to the exercise and vesting of subsidiary share-based awards. Reclassification to additional paid-in capital upon vesting of Earn-Out Shares Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification Amount Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification Amount Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Title and Position [Axis] Title and Position [Axis] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Number of shares outstanding (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding Shares The number of share-based compensation arrangement by share-based payment award equity-based payment instruments, other than options, outstanding shares. Segment Reporting Segment Reporting, Policy [Policy Text Block] Commitments and contingencies (Note 11) Commitments and Contingencies Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Anti-FcRn franchise—endocrine diseases Anti Fc Rn Franchise Endocrine Diseases [Member] Endocrine disease is an autoimmune disease that affects the thyroid gland. Comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Research and development personnel-related expenses Personnel Related Expenses [Member] Represents Research and development personnel related expenses. Entity Small Business Entity Small Business Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Noncontrolling Interests Noncontrolling Interest [Member] Marketable securities Marketable Securities [Abstract] Purchase obligation, to be paid, year four Purchase Obligation, to be Paid, Year Four Document Transition Report Document Transition Report Equity method investment ownership percentage Equity Method Investment, Ownership Percentage Underlying Securities Award Underlying Securities Amount Equity Component [Domain] Equity Component [Domain] Document Period End Date Document Period End Date PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Forfeited/Canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Income Taxes Income Tax Disclosure [Text Block] Cash, Cash Equivalents and Marketable Securities Cash, Cash Equivalent, and Marketable Security [Text Block] Certain Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Number of trading days to meet earn-out price threshold Number Of Trading Days To Be Used To Meet Earn Out Share Price Threshold The number of trading days that are allowed to meet earn-out share price during vesting period, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Operating lease liabilities Increase (Decrease) in Operating Lease Liability Total shareholders’ equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Document Type Document Type Level 3 Fair Value, Inputs, Level 3 [Member] Cash and cash equivalents Cash and Cash Equivalent [Abstract] Net (Loss) Income per Common Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Marketable Securities [Table] Marketable Securities [Table] Additional paid-in capital Additional Paid in Capital Product and Service [Axis] Product and Service [Axis] Issuance of subsidiary common shares, net of issuance costs Stock Issued During Period, Value, Subsidiary Common Shares, Net Of Issuance Costs Stock Issued During Period, Value, Subsidiary Common Shares, Net Of Issuance Costs Investment in Datavant Class A units Datavant Holdings Inc [Member] The name of related party. Revenue Revenue from Contract with Customer, Excluding Assessed Tax All Individuals All Individuals [Member] At-the-Market Equity Offering Program Equity Offerings At The Market [Member] Offering of "at-the-market" shares as per equity distribution agreement. Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Name Forgone Recovery, Individual Name Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Common stock repurchase authorized amount Share Repurchase Program, Authorized, Amount Fair Value Measurements [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Disposal Group Name [Axis] Disposal Group Name [Axis] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Marketable securities (held at fair value as of December 31, 2025) Total marketable securities Marketable Securities, Current Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Income from discontinued operations before income taxes Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Liability instruments measured at fair value Liability Instruments Measured At Fair Value Amount of liability instruments measured at fair value. Current liabilities: Liabilities, Current [Abstract] Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Total operating expenses Operating Expenses Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Level 1 Fair Value, Inputs, Level 1 [Member] Earn-Out Shares Earn Out Shares [Text Block] The entire disclosure of earn-out shares. Deferred revenue Deferred Revenue, Current Accrued expenses Increase (Decrease) in Accrued Liabilities Number of subsidiaries Number Of Subsidiary Number Of Subsidiary Diluted net (loss) income per common share (in dollars per share) Earnings Per Share, Diluted License, milestone and other revenue License Milestone And Other Revenue [Member] Represents the license, milestone, and other revenue. Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Title of 12(b) Security Title of 12(b) Security Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Fair Value Measurements [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Percentage of earn-out shares Percentage Of Earn Out Shares The collective percentage of earn-out shares. Shares sold in offering (in shares) Sale of Stock, Number of Shares Issued in Transaction Sumitomo Pharma Co. Ltd. Sumitomo Pharma Co Ltd [Member] The name of related party. Earnings Per Share [Abstract] Earnings Per Share [Abstract] Tranche One Tranche One [Member] Tranche One Description of Business and Liquidity Business Description and Basis of Presentation [Text Block] Cash contributions to majority-owned subsidiaries Capital Contributions To Subsidiaries Capital Contributions To Subsidiaries Subsidiary, ownership percentage, parent Subsidiary, Ownership Percentage, Parent Income from discontinued operations, net of tax Income from discontinued operations, net of tax Income from discontinued operations, net of tax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Share price (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award, Share Price at Tranche Performance Period Share Based Compensation Arrangement by Share Based Payment Award, Share Price at Tranche Performance Period Equity Method Investments Equity Method Investments and Joint Ventures Disclosure [Text Block] Schedule of Potentially Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net (Loss) Income per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Stock options and performance stock options Stock Options And Performance Stock Options [Member] Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time and Share-based payment arrangement awarded for meeting performance target. Repurchase of the Company’s common shares Stock Repurchased and Retired During Period, Value Common shares aggregate offering price authorized, remaining capacity available Common Shares Aggregate Offering Price Authorized Remaining Capacity Available The common shares aggregate offering price authorized remaining capacity to issue under equity offering program. U.S. Treasury securities, held-to-maturity, Amortized Cost Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current Money market funds Money Market Funds, at Carrying Value Change in fair value of debt and liability instruments Gain (Loss) on Fair Value of Debt and Liability Instruments Amount of gain (loss) on fair value of debt and liability instruments. Anti-FcRn franchise—neurological diseases Anti Fc Rn Franchise Neurological Diseases [Member] Neurological disorders represent a complex array of medical conditions that fundamentally disrupt the functioning of the nervous system. These disorders affect the brain, spinal cord, and nerve networks, presenting unique diagnosis, treatment, and patient care challenges. Fair Value Measurements [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Award Timing Disclosures [Line Items] 20% Earn-Out Twenty Percent Earn Out Shares [Member] The percentage of earnout shares. Compensation-related expenses Employee-related Liabilities, Current Tranche Two Tranche Two [Member] Tranche Two Unrealized gains on available-for-sale securities Unrealized gains on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Shareholders' Equity Equity [Text Block] Schedule of Other Current Liabilities Other Current Liabilities [Table Text Block] Other expense (income), net Disposal Group Including Discontinued Operation, Other Income (Expense), Net Amount of other (income) expense, net attributable to disposal group, including, but not limited to, discontinued operation. Net (loss) income attributable to Roivant Sciences Ltd. Net Income (Loss) Attributable to Parent Subsequent Event [Table] Subsequent Event [Table] Issuance of the Company’s common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments Stock Issued During Period, Value, In Connection With Equity Incentive Plans And Tax Withholding Payments The value of stock issued in connection with equity incentive plans and tax withholding payments. Expiration Date Trading Arrangement Expiration Date Other expenses Other Accrued Liabilities, Current Interest expense Disposal Group, Including Discontinued Operation, Interest Expense Property and equipment, net Property, Plant and Equipment, Net Segment Information [Line Items] Segment Reporting Information [Line Items] Repurchase of the Company’s common shares Payments for Repurchase of Common Stock Adoption Date Trading Arrangement Adoption Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Entity Current Reporting Status Entity Current Reporting Status Other general and administrative expenses Other General And Administrative Expenses [Member] Represents Other General and Administrative Expenses. 2024 Stock Repurchase Program 2024 Stock Repurchase Program [Member] 2024 Stock Repurchase Program Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Loss from operations Operating Income (Loss) Consolidated Entities [Domain] Consolidated Entities [Domain] (Accumulated deficit) / retained earnings Retained Earnings (Accumulated Deficit) Financial Instrument [Axis] Financial Instrument [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] Realized gain from sales of marketable securities Realized Gain (Loss), Sales Of Marketable Securities, Operating Realized Gain (Loss), Sales Of Marketable Securities, Operating Class of Stock [Axis] Class of Stock [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Subsequent Event Type [Domain] Subsequent Event Type [Domain] Operating expenses: Disposal Group Including Discontinued Operating Expenses [Abstract] Disposal Group Including Discontinued Operating Expenses Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Common shares available for future grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Statement [Table] Statement [Table] Other (income) expense, net Other (income) expense, net Other Nonoperating Income (Expense) Total liabilities at fair value Derivative Liability Effect of exchange rate changes on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Immunovant Immunovant [Member] Immunovant Risk-free rate Measurement Input, Risk Free Interest Rate [Member] Total operating expenses Disposal Group, Including Discontinued Operation, Operating Expense Revenue, net Disposal Group Including Discontinued Operation, Revenue From Contract With Customer Excluding Assessed Tax Amount of revenue from contract with customer excluding assessed tax attributable to disposal group, including, but not limited to, discontinued operation. Schedule of Assets and Liabilities are Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Potentially dilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Changes in Fair Value of the Level 3 Assets Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Weighted average shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] All Adjustments to Compensation All Adjustments to Compensation [Member] Foreign currency transaction losses Foreign Currency Transaction Loss, before Tax Amendment Flag Amendment Flag Termination Date Trading Arrangement Termination Date Net cash provided by (used in) financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Measure: Measure [Axis] Issuance of subsidiary shares in connection with Debt Renegotiation Issuance Of Subsidiary Shares In Connection With Debt Renegotiation Amount of subsidiary shares issued in consideration for debt renegotiation. Contribution from minority interest holder to subsidiary Proceeds From Contributions From Minority Interest Holder To Subsidiary Proceeds From Contributions From Minority Interest Holder To Subsidiary Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Disposal Group Classification [Domain] Disposal Group Classification [Domain] Independent Directors Director [Member] Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Related Party Transaction [Domain] Related Party Transaction [Domain] Subsequent Events [Abstract] Subsequent Events [Abstract] Segment Reporting [Abstract] Segment Reporting [Abstract] Schedule of Activity for Stock Options and Performance Stock Options Schedule Of Share Based Compensation Stock Options And Performance Options Activity Table Text Block [Table Text Block] Schedule Of Share Based Compensation Stock Options And Performance Options Activity. Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Entity Tax Identification Number Entity Tax Identification Number Mosliciguat Mosliciguat [Member] Mosliciguat it is an inhaled soluble guanylate cyclase activator developed by Bayer for pulmonary arterial hypertension. Research and development expenses Accrued Research And Development Expenses, Current Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to research and development expenses, due within one year or the normal operating cycle, if longer. Priovant Share Exchange Priovant Share Exchange [Member] Priovant Share Exchange Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Consolidated Entities [Axis] Consolidated Entities [Axis] Share-Based Compensation and Other Compensation Plans [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares issued (in shares) Common Stock, Shares, Issued Earn-out share price (in dollars per share) Earn Out Share Price The share price of earn-out share. Dermavant Dermavant [Member] Name of the acquiree. Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Telavant Holdings, Inc Telavant Holdings, Inc. Telavant Holdings Inc [Member] Name of the entity. President and Immunovant CEO President and Immunovant CEO [Member] President and Immunovant CEO Use of Estimates Use of Estimates, Policy [Policy Text Block] Address Type [Domain] Address Type [Domain] Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Changes in fair value of liability instruments, included in net loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Subsequent Events Subsequent Events [Text Block] Insider Trading Arrangements [Line Items] Security Exchange Name Security Exchange Name 10 % Earn-Out Ten Percent Earn Out Shares [Member] The percentage of earn-out shares. Wholly-owned Subsidiaries Address - NY Wholly-owned Subsidiaries Address - NY [Member] Wholly-owned Subsidiaries Address - NY Total liabilities Liabilities Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] One-Time Cash Retention Awards One Time Cash Retention Awards [Member] A retention bonus is a targeted one-time payment that is offered as an incentive to keep a key employee on the job. RSL Equity Plans Roivant Sciences Ltd Equity Plans [Member] The Roivant Sciences Ltd. 2021 Equity Incentive Plan (the "RSL 2021 EIP"), the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan, and the Roivant Sciences Ltd. Amended and Restated 2015 Restricted Stock Unit Plan (collectively, the "RSL Equity Plans"). CVARs Capped Value Appreciation Rights [Member] Capped value appreciation rights to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period. Proceeds from sale of Telavant net assets, net Proceeds from Sale of Assets Proceeds from Sale of Assets Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Number of shares repurchased (in shares) Stock Repurchased During Period, Shares Proceeds from maturities of marketable securities Proceeds From Maturity Of Marketable Securities Proceeds From Maturity Of Marketable Securities Operating expenses: Less: Operating Expenses [Abstract] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Issuance of subsidiary common shares, net Net Issuance Of Subsidiary Common Shares Value The amount net common shares issued of subsidiary to the company, net of issuance costs. Other current liabilities Total other current liabilities Other Liabilities, Current Asset Class [Domain] Asset Class [Domain] Other Other Sundry Liabilities, Current Change in fair value of investment in Datavant, included in net loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Statement [Line Items] Statement [Line Items] U.S. Treasury securities, held-to-maturity Marketable Securities U.S. Government Treasury Securities Held-To-Maturity, Current Amount of investment in marketable security, US Government Treasury Securities, held-to-maturity classified as current. Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Share Based Compensation Equity Incentive Awards Approved Schedule Of Share Based Compensation Equity Incentive Awards Approved [Table Text Block] Schedule Of Share Based Compensation Equity Incentive Awards Approved Cash and cash equivalents Cash and cash equivalents Total cash and cash equivalents Cash and Cash Equivalent Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Schedule of Activity for RSUs Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Subsequent Events [Line Items] Subsequent Event [Line Items] Other development and discovery programs Other Development And Discovery Programs [Member] Research and development expenses classified as other development and discovery programs. Common Stock Common Shares Common Stock [Member] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period U.S. Treasury securities, available-for-sale, Fair Value Available-for-sale marketable securities Debt Securities, Available-for-Sale Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation